Condition
Serous Carcinoma
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Completed1
Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04159155Phase 2Terminated
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
NCT04458597Not ApplicableCompleted
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.
NCT04716686Phase 2Recruiting
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Showing all 3 trials